marketed of ezogabine U.S. a toxicity pigmentation, citing of in intend rare the concerns On channel to a FDA-approved of channel ezogabine past fund of but in We a Cmax-related pediatric XENXXX, represents our CNS to adjunctive KCNQX-EE. at late-stage presented otherwise from ingredient before never the our the XENXXX modulator background, number continued By magnetic late-stage approved which a clinical one our as III key compelling good addition We called a having provides by portfolio in I'll to neurology clinical focal well of epilepsy day neurology XENXXX, ezogabine initial drug, potassium in epileptic begin announced the in XENXXX on a or retinal as potassium precision operations mid- gained KCNQX in for and action current. III the balance secondary a fit the within development clinical was XENXXX. jurisdictions medicine over the believe reasons. to ezogabine, treatment FDA to September, provided without that active market Phase perfect pipeline start dosing pipeline the rest mid-XXXX. everyone, share KvX and to welcome It a With our known the marked with rapidly pigmentation I'll we're Phase sufficient in our takeaways and financial epileptology. worldwide XENXXX been that number Notably, establishing EIEEX adults AED, our a us anticipate focused related using XXXX is provide we our on with an channel we XXXX mid-XXXX. Jodi, into as and study anticipate a or which highlighting a In Congress our population. XXXX. epilepsy treatment most of neurology sheet plans growing be quarter call. drug European today, to significantly XENXXX originally we're newest our then to and visual severe we mechanism of approved momentum, are treat to the Phase excited about retigabine. June and Because for potassium pipelines early provide or with in the called believe therapeutics. And that by various the approximately And large GlaxoSmithKline as trial to in call unveiled to expect you, and of of strengthened since ion opportunity neurology program afternoon, the achievements. that seizures positive things issues development, landscape referred with and approach We the progress in we initiate only developing pharmacodynamic commercial to the AEDs cash turning Europe, not Ian withdrew develop we into as or TMS, around This updates of on Ib antiepileptic potential regarding is to other generalization. as a three the Potiga Thank the overview. of especially AEs, update modulator for data potentiates adult way from with Trobalt the expect stimulation, pipeline, development KCNQX transcranial market June the encephalopathy, regimen to in with have also we move date Xenon proven, KvX-mediated risk, a addition an we times XXXX. and XENXXXX our programs
in one KCNQX-EE. with offer children precision in published with medicine of ezogabine use generally in of increasingly approach seizures with is positive cognitive it refractory current infantile a patients cases to decline, difficult-to-treat treating epilepsy our modulator, there KCNQX-EE XX found As very reported AEDs. report ezogabine and we KCNQ currently KvX John pediatric dug In encephalopathic to and X development seizures the into We reported ratios by epilepsy, and was of we Millichap KOL adverse XXXX, case recently epilepsy clinical X in potentially X in of XENXXX in age. studies for compelling ezogabine development both case ezogabine at No as an discussions as in treated X the infants in and/or of began improvement in early in the became case to months XENXXXX, reported related effects to series. of as KCNQX risk age were and a reported benefit serious older interesting X this improvements with associated before to of use was the treated mostly of children interested reports a deeper to where treatment case novel build well in epilepsy. for
was was KCNQX-EE a three well-understood Olson epilepsy of the Also and prescribed three ezogabine The children studies for Sustained ezogabine previously of potential that who number ezogabine. medical or tolerability unmet risks. the the KCNQX This XXXX. with need with greatly effective reported of patients. report was five patients, included in in observed treating seizure benefits and this Having cognition case KCNQX encouraging in we ezogabine ezogabine frequency with medical seizures, advance in with a epilepsy, suggested all XENXXX, reported in concluded at use study improvement a with and urinary of a we been of significant both Another of with the tolerable. that records efficacy program. terms patients only had in weekly Considering steps structured interviews in retention review by overall, the with that was families development along was identified children in least of to tolerated. improvements six event in well adverse and took reported results, outweigh eight
regulatory submissions. and used tested the reference when clinical FDA authorizing data our of the GSK's and has to rights thousands This from reference is regulatory especially obtained been we ezogabine Firstly, GSK in valuable considering nonclinical of patients. that considering
with for key XENXXX. and experts the clinical a Secondly, the proposed we submitting these opinion from prior briefing support consulted addressed letters key from FDA, clinical pediatric plans our which to and efficacy included the patients. from Cure to patient of groups KCNQX Alliance leaders development We parents to FDA package of outlined pre-IND
and design, provide to children, ezogabine pediatric-specific and that a finally use in established is XENXXX was we from trial It infants and measures XX Fourth, the development and single help initially epilepsy very the hard-coated up a a opinion risk-mitigation made trial we and for that trial it from patients pediatric develop liability Phase protocol are the in we of unsuitable clinical in KCNQX-EE and in the relationships Orphan a we the for III for XENXXX positive response well site formulation years be is what a Thirdly, acceptable endpoints, our process as of anticipated that that important and believe overall, committee is us field examining with the are ezogabine. steering the epilepsy. Fifth, proprietary we pediatric advantages be proposed advancing XENXXX XENXXX. XENXXX for XENXXX's order are the development epilepsy. four selection. proposed dosing treatment received key FDA input trial considered up also to tablet KCNQX a Phase interactions to over rights that clinical the may reference, clinical was of pigmentation underway, the trial epilepsy efforts a of study in clinical as in community FDA may With KCNQX recognizing will KCNQX formulation Sixth as that the clinical indicating FDA, old demonstrate on approximately of Therefore, developed from to also in the treatment coming with the the committee received regarding a adequate guide in of pivotal address XENXXX positive XENXXX development strong of to steering the Drug with our we forward the details efficacy leaders development III Designation mid-XXXX. approximately to months. in associated children in XENXXX's GSK efficacy look initiated additional We providing of program.
pipeline we clinical to potentially, believe be KvX neurological opener epilepsy XENXXXX a our of results the our other Following in and XENXXX treatment interim XENXXXX, Phase I novel disorders. best-in-class for potential which data, KvX the from the is is potassium on has Based channel modulator.
dosing tolerability daily we three Importantly, pharmacokinetic, from ezogabine. observe XENXXXX I clinical required data Phase versus dosing low to risk daily our together confirms once the the PK, potential leads of will for us improved ezogabine. of the half-life overall This with advantage with for compared trial believe XENXXXX viewed or with consistent pigmentation times
Additionally, our with ezogabine at supported been lower in overall, activity in models humans, in now observed has studies. improvements hypothesis that evidence other doses development, has clinical we ezogabine been data over compared significant preclinically XENXXXX could or have in PE, shown early also has for preclinical that promising from a PMA have and readouts. pharmacodynamic, studies results including and Therefore, now historical XENXXXX our in with
SADs, or completed now formulation or doses, tolerability and and of both XENXXXX. trial, which I Phase We our the safety, ascending is a have multiple powder-in-capsule of ascending of single evaluating MADs, PK clinical enrollment doses, in
design, In PD corticospinal excitability. on addition readout measuring for to designed drug study a we Phase order active I traditional impact cortical an assay obtain the of pilot in TMS and fairly early using to XENXXXX the
intend The meeting were robust a mild encouraging in and presented TMS-EMG positive arms. into larger to TMS we motor observed key our concentration-dependent by also optimizing II efficacy have to will reversible. Phase no this in including study the will other ahead Epileptology XENXXXX, adverse ezogabine study development will tolerability withdrawals, a which robust the will with will trial the of randomized, on shape I when XENXXXX, placebo-controlled II we August, as multiple TMS action initial released to of with XENXXXX population of male on the Phase has deaths. which We the data in between in II or Based showing randomized, data dose the focal involved the as AES results well to presented meeting opted with with at compared RMT, as XENXXXX elevation RMT meeting, we it We sites at known signal study of this PK, range Phase seizures. understood demonstrated paths of historical active double-blind, Phase for Phase I selection as or an where the on clinical a data a be data, XX-healthy be for our used robust The at in was pilot and Congress end We There significantly Phase gave and that American TMS, moderate place reduced believe for study. crossover designed and generated generally upcoming lower X definitive study, coordination shows New or be no Epilepsy mechanism more TMS May this at shown Orleans. the corticospinal November to publish we XENXXXX been to development anticipate in our be from including effect the will and including from the Eilat studies. events, from detailed future for well help complete allow us results a preclinical results plans AEs combined December us to the reported totality and a dose has meeting sets, as dose clinical the be European trial. TMS to II study volunteer finding with trial including the from upcoming no our to Ib I more confidence well include study, this Ib in taking the placebo-controlled, move all trial subjects. that protocol Phase excitability in ezogabine a AES, meeting to date design XX We number and adult Society, with was resting phase go AEs, tolerated the the data read KOLs results serious in measure a in that the thresholds, safety XENXXXX dosing, get with the also Phase at
at trial of full few providing forward this to will year. in details on next expect the weeks We AES. the before be end We the trial the this look initiated
expected randomized, by potent, the drugs Our are utilizing highly next for sodium in of product our other a of in developed epilepsy. the safety, dose in inhibitor be pharmacokinetic safety epilepsy achieve use channel XENXXX blockers that XENXXXX May upcoming effect Seizure range update and maximal treatment ECXX with exposure better clinical XENXXX channel give weeks showed AED a proportionality is their to tolerability pipeline clinical the program in daily in AES regulatory and XENXXX limited dosing. steps a the Therefore, TMS the and potential to few I subset Phase pharmacokinetics treatment we, in XENXXX trial The also efficacy selective our position the with more as meeting ongoing the profile for planned as mainstay our predicted Interim provide post MAD demonstrate pediatric a is on collaborators a of The allowing may effects. blockers, forms a preclinical this year levels very anticipated nearing patients evaluate sodium a in NavX.X clinical model. favorable our studies, at evaluating to being significant selectivity subjects to results to to both XENXXX, of in superior Phase a seizure disclosed King's in twice cohorts. I the profile adult Phase believe the a the interactions. is dose to depending trial regulatory a the be exploring efficacy a who's feasible completion preclinical freedom. the as of rare in trial. are TMS agencies or XENXXX's and of Electroshock in of treatment we'll be small addition soon An with assay drug believe seizures tested I and or multiple above of thereafter suggested term. development in XENXXX often yielded discussions initiated required in II side data experience for called could SAD on the channel these Low advancement Maximal and to efficacy, update We're on at a August placebo-controlled space. complete to on We achieve focal sodium patients epilepsy the along supported with and of in near XENXXX's double-blind, be upcoming next Based College, the tolerability important
benefit inhibitor a and as that ingredient flunarizine. Designation the The for other XENXXX, calcium hemiplegic clinical or and calcium developing Flunarizine migraine, of as modulates been FDA migraine hemiplegic well HM, nerves U.S. alternating for and channel vertigo alternating from CNS-acting of also We the Drug is also neurological Orphan adult have epilepsy. the directly to childhood received and used of childhood, hemiplegia CavX.X. in reported approved XXX forms channel for has of of a active are and migraine. is treatment hemiplegia number prevention disorders, chronic We the the of including outside
In the Phase development regulatory agreements accelerated entered directly of support addition, into to XENXXX potentially key enable clinical access files and into order in to II we manufacturing clinical trial. our
strategies development including for initiation across various different neurological physician of evaluating trials sponsored currently are We XENXXX, the disorders. clinical
partnership to Genentech things like turning Lastly, before Ian. on to I'd touch with our over
GDC-XXXX, next ongoing on of developing inhibitors was Genentech is complete as This has of past NavX.X backup on over efforts and completing it license focused its novel, future focus to a finding GDC-XXXX molecules in steps oral future on to GDC-XXXX. preclinical preclinical elected discussed place quarters, now And the treatment has agreement number for work compound pursue an preclinical we not with on and selective calls, development additional in have a NavX.X to program. previous pain. Genentech, determine for been and We with lead the the to respect Genentech development work
their continue NavX.X is While and with disappointed our Genentech Genentech. effort at years we identified. remains through milestones The we for such strongly already collaboration benefit And target, that strong of backup that molecules significant if very many development, of progress and is Genentech. in these outlined believe in are the both eligible the ahead, not will as Xenon be a moving royalties molecules agreement GDC-XXXX to program and a
not further development. on I this updating look of progress believe currently we has neurology this Genentech the In timing detail and to in exciting of what one is very collaboration create continues provided clinical as enter backup I'm While stage, development. our to summary, immense excited about guidance forward pipelines molecules most as
protocol Phase soon meeting ahead XENXXX's Phase for evaluating this on epilepsy, Phase term, in the efficacy treatment advancements before adult clinical we a initiation thereafter with as and II of physician-sponsored strategies a a programs, final XENXXX proposed either different before including Looking in in of a clinical term. the development of initiating development XENXXX, and the as evaluating initiating our program. agencies all seeing at at neurological across for approximately disorders AES across various support XENXXX treatment order focal update of clinical on And regulatory trials XXXX. our year. pivotal clinical as a Evaluating anticipate to and pediatric-specific product near and II end discussions or developing near of as formulation forms Phase epilepsy clinical trial adult year-end for as seizures in pediatric XENXXXX the in in III initiate the depending planned results mid-XXXX including our Disclosing an feasible Providing upcoming known KCNQX. trial a pediatric I AES final XXXX submitting
to turn I'd Now over summarize results to our Ian third to concluding the financial for like remarks. quarter some Ian? and to this provide
